290 related articles for article (PubMed ID: 19659459)
21. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation.
Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
J Alzheimers Dis; 2006 Mar; 9(1):1-12. PubMed ID: 16627930
[TBL] [Abstract][Full Text] [Related]
22. O-GlcNAcylation of protein kinase A catalytic subunits enhances its activity: a mechanism linked to learning and memory deficits in Alzheimer's disease.
Xie S; Jin N; Gu J; Shi J; Sun J; Chu D; Zhang L; Dai CL; Gu JH; Gong CX; Iqbal K; Liu F
Aging Cell; 2016 Jun; 15(3):455-64. PubMed ID: 26840030
[TBL] [Abstract][Full Text] [Related]
23. Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer's disease.
Zheng BW; Yang L; Dai XL; Jiang ZF; Huang HC
Neurol Res; 2016 Feb; 38(2):177-86. PubMed ID: 27078700
[TBL] [Abstract][Full Text] [Related]
24. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
25. Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer's disease and type 2 diabetes.
Khalaf SS; Hafez MM; Mehanna ET; Mesbah NM; Abo-Elmatty DM
Naunyn Schmiedebergs Arch Pharmacol; 2019 Jun; 392(6):685-695. PubMed ID: 30759264
[TBL] [Abstract][Full Text] [Related]
26. O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond.
Yuzwa SA; Vocadlo DJ
Chem Soc Rev; 2014 Oct; 43(19):6839-58. PubMed ID: 24759912
[TBL] [Abstract][Full Text] [Related]
27. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies.
Pinho TS; Correia SC; Perry G; Ambrósio AF; Moreira PI
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2048-2059. PubMed ID: 30412792
[TBL] [Abstract][Full Text] [Related]
28. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.
Liang Z; Liu F; Iqbal K; Grundke-Iqbal I; Wegiel J; Gong CX
J Alzheimers Dis; 2008 Apr; 13(3):295-302. PubMed ID: 18430997
[TBL] [Abstract][Full Text] [Related]
29. Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease.
Qian W; Yin X; Hu W; Shi J; Gu J; Grundke-Iqbal I; Iqbal K; Gong CX; Liu F
J Alzheimers Dis; 2011; 23(4):617-27. PubMed ID: 21157033
[TBL] [Abstract][Full Text] [Related]
30. Rapamycin inhibits activation of AMPK-mTOR signaling pathway-induced Alzheimer's disease lesion in hippocampus of rats with type 2 diabetes mellitus.
Sun Q; Wei LL; Zhang M; Li TX; Yang C; Deng SP; Zeng QC
Int J Neurosci; 2019 Feb; 129(2):179-188. PubMed ID: 29962282
[TBL] [Abstract][Full Text] [Related]
31. Ribosylation triggering Alzheimer's disease-like Tau hyperphosphorylation via activation of CaMKII.
Wei Y; Han C; Wang Y; Wu B; Su T; Liu Y; He R
Aging Cell; 2015 Oct; 14(5):754-63. PubMed ID: 26095350
[TBL] [Abstract][Full Text] [Related]
32. Effect of amyloid-Β (25-35) in hyperglycemic and hyperinsulinemic rats, effects on phosphorylation and O-GlcNAcylation of tau protein.
Lozano L; Guevara J; Lefebvre T; Ramos-Martinez I; Limón D; Díaz A; Cerón E; Zenteno E
Neuropeptides; 2017 Jun; 63():18-27. PubMed ID: 28427866
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
Yang Y; Zhang J; Ma D; Zhang M; Hu S; Shao S; Gong CX
J Alzheimers Dis; 2013; 37(3):637-48. PubMed ID: 23948890
[TBL] [Abstract][Full Text] [Related]
34. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease.
Mendonça CF; Kuras M; Nogueira FCS; Plá I; Hortobágyi T; Csiba L; Palkovits M; Renner É; Döme P; Marko-Varga G; Domont GB; Rezeli M
Neurobiol Dis; 2019 Oct; 130():104509. PubMed ID: 31207390
[TBL] [Abstract][Full Text] [Related]
35. Increased Ratio of Global
Huang R; Tian S; Han J; Cai R; Lin H; Guo D; Wang J; Wang S
Front Physiol; 2019; 10():110. PubMed ID: 30837891
[No Abstract] [Full Text] [Related]
36. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes.
Yang Y; Ma D; Wang Y; Jiang T; Hu S; Zhang M; Yu X; Gong CX
J Alzheimers Dis; 2013; 33(2):329-38. PubMed ID: 22936005
[TBL] [Abstract][Full Text] [Related]
37. Amylin as a potential link between type 2 diabetes and alzheimer disease.
Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Riverol M; Marcilla I; de Andrea CE; Sánchez-Arias JA; Del Mar Carmona-Abellan M; Marti G; Erro ME; Martínez-Vila E; Tuñon MT; Luquin MR
Ann Neurol; 2019 Oct; 86(4):539-551. PubMed ID: 31376172
[TBL] [Abstract][Full Text] [Related]
38. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.
Gong CX; Iqbal K
Curr Med Chem; 2008; 15(23):2321-8. PubMed ID: 18855662
[TBL] [Abstract][Full Text] [Related]
39. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.
Kim DH; Huh JW; Jang M; Suh JH; Kim TW; Park JS; Yoon SY
Neurobiol Dis; 2012 Apr; 46(1):52-8. PubMed ID: 22245388
[TBL] [Abstract][Full Text] [Related]
40. Amyloid-β and islet amyloid pathologies link Alzheimer's disease and type 2 diabetes in a transgenic model.
Wijesekara N; Ahrens R; Sabale M; Wu L; Ha K; Verdile G; Fraser PE
FASEB J; 2017 Dec; 31(12):5409-5418. PubMed ID: 28808140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
